Page last updated: 2024-11-08

ampelopsin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ampelopsin: hepatoprotective agent; isolated from Hovenia dulcis; RN given for (2R-trans)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(+)-dihydromyricetin : An optically active form of dihydromyricetin having (2R,3R)-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Hoveniagenus[no description available]RhamnaceaeThe buckthorn plant family, of the order Rhamnales, includes some species with edible fruits and some that are medicinal.[MeSH]

Cross-References

ID SourceID
PubMed CID161557
CHEMBL ID3348861
CHEBI ID28429
SCHEMBL ID723736
MeSH IDM0277279

Synonyms (56)

Synonym
c15h12o8
(2r-trans)-2,3-dihydro-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4h-1-benzopyran-4-one
ampelopsin (flavanol)
flavanone, 3,3',4',5,5',7-hexahydroxy-
4h-1-benzopyran-4-one, 2,3-dihydro-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-, (2r-trans)-
3,3',4',5,5',7-hexahydroxy-2,3-dihydroflavanonol
ampelopsin
(+)-ampelopsin
dihydromyricetin ,
C02906
(+)-dihydromyricetin
27200-12-0
(2r,3r)-3,5,7,3',4',5'-hexahydroxyflavanone
(2r,3r)-3,3',4',5,5',7-hexahydroxy-2,3-dihydroflavanonol
ampeloptin
(2r,3r)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-2,3-dihydro-4h-chromen-4-one
(2r,3r)-2,3-dihydro-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4h-1-benzopyran-4-one
(2r,3r)-dihydromyricetin
CHEBI:28429 ,
2B89FBAC-4DD1-44C9-BE2A-9D0C173BDFD8
(2r,3r)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-4-one
4h-1-benzopyran-4-one, 2,3-dihydro-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-, (2r,3r)-
(2r,3r)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-2,3-dihydrochromen-4-one
DIHYDROMYRICETIN - AMPELOPTIN
A818952
dihydro-myricetin
unii-kd8qnd6427
kd8qnd6427 ,
NCGC00346604-01
ampelopsin [mi]
telocapil
dihydromyricetin [inci]
myriceline spe
S2399
SCHEMBL723736
AKOS022168215
CS-3809
Q-100341
HY-N0112
DTXSID50181676
CHEMBL3348861
AC-8004
dihydromyricetin (dih-myr)
bdbm212434
dihydromyricetin, analytical standard
(2r,3r)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-one
AS-71702
dihydromyricetin, >=98% (hplc)
mfcd00189451
SW219328-1
Q422305
dihydromyricetin (ampeloptin)
HMS3884B17
CCG-267699
ampelopsin;ampeloptin
D5464

Research Excerpts

Overview

Ampelopsin (AMP) is a natural flavonoid that has been found to possess antidiabetic and antioxidative activities. Ampelopsin is a bioactive flavanonol found in Hovenia dulcis Thunb.

ExcerptReferenceRelevance
"Ampelopsin (AMP) is a natural flavonoid that has been found to possess antidiabetic and antioxidative activities."( Ampelopsin inhibits high glucose-induced extracellular matrix accumulation and oxidative stress in mesangial cells through activating the Nrf2/HO-1 pathway.
Dong, C; Gao, S; Li, H; Qiao, Y; Wu, G, 2020
)
2.72
"Ampelopsin is a bioactive flavanonol found in Hovenia dulcis Thunb."( Hovenia dulcis Thunb. and its active compound ampelopsin inhibit angiogenesis through suppression of VEGFR2 signaling and HIF-1α expression.
Han, JM; Jung, HJ; Lim, HN, 2017
)
1.43
"Ampelopsin is a well-known flavonoid which has variety of biological and pharmacological actions including anticancer effects and induction of apoptosis on the several cancer cell lines. "( Ampelopsin sodium induces mitochondrial-mediated apoptosis in human lung adenocarcinoma SPC-A-1 cell line.
Chao, L; Cui, MX; Jiang, JF; Liu, ZR; Wu, YJ; Zhai, J; Zhao, YF, 2016
)
3.32
"Ampelopsin (AMP) is a well-known flavonoid that exerts a number of biological and pharmacological effects including anticancer effects against several cancer cell lines. "( Ampelopsin Induces DR5-Mediated Apoptotic Cell Death in EBV-Infected Cells through the p38 Pathway.
Hur, DY; Kim, KH; Kim, YS; Yun, SM, 2020
)
3.44
"Ampelopsin is a natural flavonol that has strong antioxidant activity, but little information is available regarding its antidiabetic effect."( Ampelopsin protects endothelial cells from hyperglycemia-induced oxidative damage by inducing autophagy via the AMPK signaling pathway.
Kang, C; Liang, X; Mi, M; Shi, L; Wan, J; Zhang, T; Zhou, Y; Zhu, J,
)
2.3
"Ampelopsin appears to be a potent anti-tumor agent that was firstly discovered in the transplant human lung cancer cell line GLC-82 in nude mice in vivo."( [Anti-tumor effects of ampelopsin on human lung cancer GLC-82 implanted in nude mice].
Liu, D; Wang, L; Wang, W; Ye, Y; Zeng, S, 2004
)
2.08
"Ampelopsin is a potent inhibitor of VEGF and bFGF expression and production in human hepatocellular carcinoma Bel-7402 cell, and may be a promising angiogenesis inhibitor."( [Inhibitory effects of ampelopsin on angiogenesis].
Liu, DY; Luo, GQ; Zeng, S, 2006
)
2.09

Effects

Ampelopsin has displayed anticancer activity in several types of cancers. There is no evidence regarding its direct effect on the migration and invasion of osteosarcoma cells.

ExcerptReferenceRelevance
"Ampelopsin has displayed anticancer activity in several types of cancers. "( Ampelopsin reduces the migration and invasion of ovarian cancer cells via inhibition of epithelial-to-mesenchymal transition.
Chen, Y; Ding, F; Li, B; Li, S; Liu, P; Liu, T; Sun, X; Wang, F; Wang, S; Yu, N; Zhang, X; Zhao, Y, 2015
)
3.3
"Ampelopsin has been suggested as a novel anticancer agent, however, there is no evidence regarding its direct effect on the migration and invasion of osteosarcoma cells. "( Ampelopsin suppresses TNF-α-induced migration and invasion of U2OS osteosarcoma cells.
Li, B; Liu, C; Wang, L; Xu, X; Yang, Y; Zhao, P, 2016
)
3.32
"Ampelopsin has anti-invasive and anti-metastatic effects on B16 melanoma."( [Anti-invasive and anti-metastatic effect of ampelopsin on melanoma].
Liu, DY; Zheng, HQ, 2003
)
2.02
"Ampelopsin has anti-invasive and anti-metastatic effects on B16 melanoma."( [Effects of ampelopsin on invasion and metastasis of B16 mouse melanoma in vivo and in vitro].
Liu, DY; Luo, GQ; Zheng, HQ, 2003
)
2.14

Actions

Ampelopsin displays a strong inhibitive role during HIV-1 absorption, incubation and acute infection. Ampelopsin can strongly enhance the chemokinesis and chemotaxis effects of neutrophilic granulocytes and moncytes.

ExcerptReferenceRelevance
"Ampelopsin can also inhibit B16 cells migration,and the inhibition rates were 51.59%, 56.51%, and 66.75% for ampelopsin at 20, 40, and 80 micromol/L, respectively (P< 0.01)."( [Anti-invasive and anti-metastatic effect of ampelopsin on melanoma].
Liu, DY; Zheng, HQ, 2003
)
1.3
"Ampelopsin displays a strong inhibitive role during HIV-1 absorption, incubation and acute infection. "( Ampelopsin, a small molecule inhibitor of HIV-1 infection targeting HIV entry.
Liu, DY; Yan, J; Yang, WH; Ye, JT; Zeng, CH; Zeng, S, 2004
)
3.21
"Ampelopsin could also inhibit B16 cells migration through PVPF in the Transwell chambers, and the inhibition rates were 51.59%, 56.51%, and 66.75% at 20 micromol x L(-1), 40 micromol x L(-1) and 80 micromol x L(-1), respectively (P<0.01)."( [Effects of ampelopsin on invasion and metastasis of B16 mouse melanoma in vivo and in vitro].
Liu, DY; Luo, GQ; Zheng, HQ, 2003
)
1.42
"Ampelopsin was shown to inhibit the proliferation of primary cultured bovine aortic endothelial cells in a concentration dependent manner in range of 6.4 - 51.2 microg/ml. "( [Inhibitory effects of ampelopsin on angiogenesis].
Liu, DY; Luo, GQ; Zeng, S, 2006
)
2.09
"Ampelopsin can strongly enhance the chemokinesis and chemotaxis effects of neutrophilic granulocytes and moncytes and exert a synergistic action with IL-8 or MCP-1 on its chemotaxis effect to neutrophilic granulocytes and monocytes."( [The chemotaxis effect of ampelopsin on the immunocytes].
Liu, DY; Luo, GQ; Zeng, S, 2006
)
2.08

Toxicity

ExcerptReferenceRelevance
" Dihydromyricetin decreased ALT, LDH and CKMB levels in mice serum, causing a significant reduction in the toxic death triggered by Adriamycin."( Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin.
Chang, L; Dai, J; Fu, Y; He, Q; Luo, P; Shao, J; Wang, J; Weng, Q; Yang, B; Yang, X; Zhu, H, 2015
)
0.42
"The anticancer drug methotrexate (MTX) is known to cause hepatotoxicity as a possibly fatal adverse effect that hinders its clinical application."( Dihydromyricetin alleviates methotrexate-induced hepatotoxicity via suppressing the ‎TLR4/NF-κB pathway and NLRP3 inflammasome/caspase 1 axis.
Awad, EM; El-Sheikh, AAK; El-Tahawy, NFG; Matouk, AI; Waz, S, 2022
)
0.72
" The study provides new inside into rh-endostatin-induced cardiotoxicity and identified a novel potential medication DHM to overcome the serious adverse effect."( The mechanism of rh-endostatin-induced cardiotoxicity and its protection by dihydromyricetin[in vivo/in vitro, C57BL/6 mice, AC16 and hiPSC-CMs].
Bian, W; Guan, X; Jiang, J; Li, W; Sun, Y; Wang, Y; Xu, C; Yu, X; Zhang, C; Zhao, Q, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" The proposed method has been successfully applied for pharmacokinetic studies of ampelopsin from rat plasma after oral administration."( Development and application of high-performance liquid chromatography for the study of ampelopsin pharmacokinetics in rat plasma using cloud-point extraction.
Tu, HH; Wang, FQ; Zeng, P; Zhou, J, 2011
)
0.82
" The plasma concentration profiles and pharmacokinetic parameters were analyzed after oral administration of dextroisomer and racemate DMY at the dose of 100 mg/kg in rats."( Determination of dihydromyricetin in rat plasma by LC-MS/MS and its application to a pharmacokinetic study.
Fang, J; Hou, X; Liu, X; Shi, C; Tong, Q; Wang, W; Xie, X; Xiong, W, 2015
)
0.42
" When co-administrated with single dose of DMY (100 mg/kg), the AUC, Cmax and T1/2 of TP were significantly enhanced by 98, 83 and 66%, respectively."( Dihydromyricetin affect the pharmacokinetics of triptolide in rats.
Cai, H; Chen, L; Deng, Y; Fang, P; Guo, L; He, G; Li, H; Tan, S; Xiang, D; Yan, M; Zhang, B, 2020
)
0.56
" The concentrations of FLC in the rat plasma were then determined by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), and the related pharmacokinetic parameters were analysed."( The Effect of Dihydromyricetin on the Pharmacokinetics of Fluconazole in Sprague-Dawley Rat Plasma, Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Dong, H; Guo, L; Jin, Y; Liu, H; Liu, L, 2023
)
0.91
" There were no significant differences in the pharmacokinetic parameters between the two groups."( The Effect of Dihydromyricetin on the Pharmacokinetics of Fluconazole in Sprague-Dawley Rat Plasma, Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Dong, H; Guo, L; Jin, Y; Liu, H; Liu, L, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" Development of COMT inhibitors can efficiently increase the bioavailability of L-dopa."( Inhibition of catechol-o-methyltransferase (COMT) by myricetin, dihydromyricetin, and myricitrin.
Jia, YH; Zhu, X, 2014
)
0.4
" Therefore, we conclude that the low bioavailability of these flavonoids may be due to their poor stability in the GI tract."( Gastrointestinal stability of dihydromyricetin, myricetin, and myricitrin: an in vitro investigation.
Fang, JG; Shi, CY; Wang, CG; Wang, MD; Wang, WQ; Xiang, D; Xiong, W, 2017
)
0.46
"A variety of beneficial pharmacological activities have been reported for dihydromyricetin (DMY), however, its oral bioavailability is poor and the intestinal absorption profiles of DMY remains unknown."( Uptake and Transport Mechanism of Dihydromyricetin Across Human Intestinal Caco-2 Cells.
Fan, L; Fang, JG; Hou, XL; Shi, CY; Wang, WQ; Xiang, D; Xiong, W, 2018
)
0.48
" DMY was poorly absorbed by a passive diffusion mechanism."( Uptake and Transport Mechanism of Dihydromyricetin Across Human Intestinal Caco-2 Cells.
Fan, L; Fang, JG; Hou, XL; Shi, CY; Wang, WQ; Xiang, D; Xiong, W, 2018
)
0.48
" However, the low oral bioavailability of DMY was one of the special concerns to be resolved for its clinical applications."( Preparation of a nanoscale dihydromyricetin-phospholipid complex to improve the bioavailability: in vitro and in vivo evaluations.
Fan, L; Fang, J; Gong, Y; Lin, T; Shi, C; Wang, W; Yin, M; Zhao, X; Zhou, X, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The bioavailability of DMY in the presence and absence of AA was compared."( Physicochemical properties of dihydromyricetin and the effects of ascorbic acid on its stability and bioavailability.
Li, Y; Sun, CC; Yin, ZP; Zhang, QF, 2021
)
0.62
" The presence of AA could significantly improve the stability of DMY, and further improve its bioavailability in rats."( Physicochemical properties of dihydromyricetin and the effects of ascorbic acid on its stability and bioavailability.
Li, Y; Sun, CC; Yin, ZP; Zhang, QF, 2021
)
0.62
" However, its poor aqueous solubility and permeability lead to the low oral bioavailability and limit its clinic application."( Self-Assembled Micelles Improve the Oral Bioavailability of Dihydromyricetin and Anti-Acute Alcoholism Activity.
Bao, S; Li, R; Ren, Q; Xu, X; Ye, J; Zhang, Q; Zhao, S; Zhu, Y, 2021
)
0.62
" Therefore, even if the bioavailability is poor, it is often added to daily food, beverages and even medicines."( Recent update on application of dihydromyricetin in metabolic related diseases.
Ding, P; Ji, G; Wang, J; Wang, Y; Wu, T; Xiang, H, 2022
)
0.72
"Dihydromyricetin (DHM) has garnered attention due to its promising antitumor activity, but its low bioavailability restricts its clinical application."( Pro-Apoptotic Effect of Zeolitic Imidazolate Framework-8 (ZIF-8)-Loaded Dihydromyricetin on HepG2 Cells.
Chen, X; Dong, M; Lou, Y; Lu, J; Mi, X; Zhan, X, 2022
)
0.72
" At the same time, increased loading of DMY and sustained release of DMY were achieved, improving bioavailability of hydrophobic drug DMY."( Injectable redox albumin-based hydrogel with in-situ loaded dihydromyricetin.
Chen, X; Cheng, W; Deng, L; Xia, T; Yang, M; Zhu, W, 2022
)
0.72
" The pharmacokinetic study revealed that DHM@GF-DLT could prolong the retention time of DHM, reduce the fluctuation of blood drug concentration, and enhance the bioavailability of DHM."( A double-layered gastric floating tablet for zero-order controlled release of dihydromyricetin: Design, development, and in vitro/in vivo evaluation.
Chen, S; Fu, X; Li, C; Li, S; Liu, H; Shi, H; Shi, J; Tian, Y; Wang, S; Wang, Y; Wu, A; Zhang, C; Zhang, D; Zhang, H; Zhang, R, 2023
)
0.91
" However, its limited stability and bioavailability posed significant challenges for further applications."( Preparation, characterization and protective effect of chitosan - Tripolyphosphate encapsulated dihydromyricetin nanoparticles on acute kidney injury caused by cisplatin.
Dong, L; Fu, H; Li, M; Li, Y; Luo, J; Shi, F; Shu, G; Tang, H; Yan, Q; Ye, G; Yin, H; Zhang, W; Zhao, L; Zhao, X; Zhong, X, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" PRACTICAL APPLICATION: Solid self-emulsifying delivery system (S-SEDS) combined the advantages of liquid self-emulsifying delivery system with those of a solid dosage form to overcome the disadvantages associated with liquid formulations is more convenient for storage and transportation in practical application."( Solid Self-Emulsifying Delivery System (S-SEDS) of Dihydromyricetin: A New Way for Preparing Functional Food.
Huang, J; Ma, Y; Sun, R; Wang, D; Wang, Q; Xia, Q, 2019
)
0.51
"2 mg/kg) with and without DMY in different dosage regimens, then a sensitive and reliable LC-MS/MS method was developed and applied to assess the pharmacokinetics of TP."( Dihydromyricetin affect the pharmacokinetics of triptolide in rats.
Cai, H; Chen, L; Deng, Y; Fang, P; Guo, L; He, G; Li, H; Tan, S; Xiang, D; Yan, M; Zhang, B, 2020
)
0.56
" DHM (50 and 100 mg/kg) was administered 10-15 min and 2 h postreperfusion followed by daily dosing for 2 more days."( Dihydromyricetin alleviates cerebral ischemia-reperfusion injury by attenuating apoptosis and astrogliosis in peri-infarct cortex.
Dinda, AK; Joshi, B; Reeta, KH; Sharma, U; Singh, D; Upadhyay, D; Wasan, H, 2022
)
0.72
" To settle these issues, extensive research has been carried out on its physicochemical properties and dosage forms to produce all kinds of DHM preparations in the past ten years."( Strategic developments in the drug delivery of natural product dihydromyricetin: applications, prospects, and challenges.
Liu, H; Shi, H; Zhang, D; Zhang, H; Zhang, R; Zhang, Z, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dihydromyricetinA hexahydroxyflavanone that is the 2,3-dihydro derivative of myricetin.
secondary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing one hydrogen and one organyl group. Secondary alpha-hydroxy ketones are also known as acyloins, and are formally derived from reductive coupling of two carboxylic acid groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
flavonol biosynthesis112
leucodelphinidin biosynthesis315
syringetin biosynthesis214
superpathway of flavones and derivatives biosynthesis1744

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency31.79110.001310.157742.8575AID1259252; AID1259253; AID1259255
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)10.00000.00403.43889.5100AID1640022
Synaptojanin-2Homo sapiens (human)IC50 (µMol)3.17000.87404.137310.0000AID1620742; AID1621365; AID1634424
Synaptojanin-1Homo sapiens (human)IC50 (µMol)15.90001.00001.00001.0000AID1620743; AID1621366
Amyloid-beta precursor proteinHomo sapiens (human)IC50 (µMol)19.05000.00053.889510.0000AID1484013; AID1802376
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)0.18000.00022.45859.9600AID1640021
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (91)

Processvia Protein(s)Taxonomy
phosphatidylinositol biosynthetic processSynaptojanin-2Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processSynaptojanin-2Homo sapiens (human)
synaptic vesicle endocytosisSynaptojanin-2Homo sapiens (human)
membrane organizationSynaptojanin-2Homo sapiens (human)
phosphatidylinositol dephosphorylationSynaptojanin-2Homo sapiens (human)
phosphatidylinositol biosynthetic processSynaptojanin-1Homo sapiens (human)
neurotransmitter transportSynaptojanin-1Homo sapiens (human)
learningSynaptojanin-1Homo sapiens (human)
synaptic vesicle primingSynaptojanin-1Homo sapiens (human)
synaptic vesicle uncoatingSynaptojanin-1Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processSynaptojanin-1Homo sapiens (human)
inositol phosphate metabolic processSynaptojanin-1Homo sapiens (human)
phosphatidylinositol metabolic processSynaptojanin-1Homo sapiens (human)
phosphatidylinositol dephosphorylationSynaptojanin-1Homo sapiens (human)
synaptic vesicle endocytosisSynaptojanin-1Homo sapiens (human)
synaptic vesicle transportSynaptojanin-1Homo sapiens (human)
membrane organizationSynaptojanin-1Homo sapiens (human)
positive regulation of endosome organizationSynaptojanin-1Homo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
cognitionAmyloid-beta precursor proteinHomo sapiens (human)
G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglial cell activationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
suckling behaviorAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activation involved in immune responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of translationAmyloid-beta precursor proteinHomo sapiens (human)
protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
intracellular copper ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
endocytosisAmyloid-beta precursor proteinHomo sapiens (human)
response to oxidative stressAmyloid-beta precursor proteinHomo sapiens (human)
cell adhesionAmyloid-beta precursor proteinHomo sapiens (human)
regulation of epidermal growth factor-activated receptor activityAmyloid-beta precursor proteinHomo sapiens (human)
Notch signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
axonogenesisAmyloid-beta precursor proteinHomo sapiens (human)
learning or memoryAmyloid-beta precursor proteinHomo sapiens (human)
learningAmyloid-beta precursor proteinHomo sapiens (human)
mating behaviorAmyloid-beta precursor proteinHomo sapiens (human)
locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
axo-dendritic transportAmyloid-beta precursor proteinHomo sapiens (human)
cholesterol metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of cell population proliferationAmyloid-beta precursor proteinHomo sapiens (human)
adult locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
visual learningAmyloid-beta precursor proteinHomo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglia developmentAmyloid-beta precursor proteinHomo sapiens (human)
axon midline choice point recognitionAmyloid-beta precursor proteinHomo sapiens (human)
neuron remodelingAmyloid-beta precursor proteinHomo sapiens (human)
dendrite developmentAmyloid-beta precursor proteinHomo sapiens (human)
regulation of Wnt signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
extracellular matrix organizationAmyloid-beta precursor proteinHomo sapiens (human)
forebrain developmentAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection developmentAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of chemokine productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-1 beta productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-6 productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of tumor necrosis factor productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of multicellular organism growthAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of neuron differentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of glycolytic processAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of JNK cascadeAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAmyloid-beta precursor proteinHomo sapiens (human)
collateral sprouting in absence of injuryAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of inflammatory responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of synapse structure or activityAmyloid-beta precursor proteinHomo sapiens (human)
synapse organizationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of calcium-mediated signalingAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular process controlling balanceAmyloid-beta precursor proteinHomo sapiens (human)
synaptic assembly at neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
neuron apoptotic processAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
neuron cellular homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAmyloid-beta precursor proteinHomo sapiens (human)
response to interleukin-1Amyloid-beta precursor proteinHomo sapiens (human)
modulation of excitatory postsynaptic potentialAmyloid-beta precursor proteinHomo sapiens (human)
NMDA selective glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of spontaneous synaptic transmissionAmyloid-beta precursor proteinHomo sapiens (human)
cytosolic mRNA polyadenylationAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAmyloid-beta precursor proteinHomo sapiens (human)
cellular response to amyloid-betaAmyloid-beta precursor proteinHomo sapiens (human)
regulation of presynapse assemblyAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection maintenanceAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of T cell migrationAmyloid-beta precursor proteinHomo sapiens (human)
central nervous system developmentAmyloid-beta precursor proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
RNA bindingSynaptojanin-2Homo sapiens (human)
phosphatidylinositol-3-phosphate phosphatase activitySynaptojanin-2Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate 5-phosphatase activitySynaptojanin-2Homo sapiens (human)
protein bindingSynaptojanin-2Homo sapiens (human)
phosphatidylinositol phosphate 4-phosphatase activitySynaptojanin-2Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 5-phosphatase activitySynaptojanin-2Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 3-phosphatase activitySynaptojanin-2Homo sapiens (human)
SH3 domain bindingSynaptojanin-2Homo sapiens (human)
PDZ domain bindingSynaptojanin-2Homo sapiens (human)
RNA bindingSynaptojanin-1Homo sapiens (human)
phosphatidylinositol-3-phosphate phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate 5-phosphatase activitySynaptojanin-1Homo sapiens (human)
protein bindingSynaptojanin-1Homo sapiens (human)
phosphatidylinositol phosphate 5-phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol phosphate 4-phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol-4-phosphate phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 5-phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 3-phosphatase activitySynaptojanin-1Homo sapiens (human)
inositol-1,4,5-trisphosphate 5-phosphatase activitySynaptojanin-1Homo sapiens (human)
SH3 domain bindingSynaptojanin-1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
serine-type endopeptidase inhibitor activityAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
heparin bindingAmyloid-beta precursor proteinHomo sapiens (human)
enzyme bindingAmyloid-beta precursor proteinHomo sapiens (human)
identical protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
transition metal ion bindingAmyloid-beta precursor proteinHomo sapiens (human)
receptor ligand activityAmyloid-beta precursor proteinHomo sapiens (human)
PTB domain bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein serine/threonine kinase bindingAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor activator activityAmyloid-beta precursor proteinHomo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (51)

Processvia Protein(s)Taxonomy
cytosolSynaptojanin-2Homo sapiens (human)
cytoskeletonSynaptojanin-2Homo sapiens (human)
plasma membraneSynaptojanin-2Homo sapiens (human)
cell projectionSynaptojanin-2Homo sapiens (human)
membrane raftSynaptojanin-2Homo sapiens (human)
perinuclear region of cytoplasmSynaptojanin-2Homo sapiens (human)
presynapseSynaptojanin-2Homo sapiens (human)
microtubuleSynaptojanin-1Homo sapiens (human)
cytosolSynaptojanin-1Homo sapiens (human)
vesicle membraneSynaptojanin-1Homo sapiens (human)
terminal boutonSynaptojanin-1Homo sapiens (human)
perinuclear region of cytoplasmSynaptojanin-1Homo sapiens (human)
synaptic membraneSynaptojanin-1Homo sapiens (human)
presynapseSynaptojanin-1Homo sapiens (human)
membrane coatSynaptojanin-1Homo sapiens (human)
clathrin coat of coated pitSynaptojanin-1Homo sapiens (human)
perinuclear region of cytoplasmSynaptojanin-1Homo sapiens (human)
presynapseSynaptojanin-1Homo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
dendriteAmyloid-beta precursor proteinHomo sapiens (human)
extracellular regionAmyloid-beta precursor proteinHomo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
nuclear envelope lumenAmyloid-beta precursor proteinHomo sapiens (human)
cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
mitochondrial inner membraneAmyloid-beta precursor proteinHomo sapiens (human)
endosomeAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulum lumenAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
Golgi lumenAmyloid-beta precursor proteinHomo sapiens (human)
Golgi-associated vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cytosolAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
clathrin-coated pitAmyloid-beta precursor proteinHomo sapiens (human)
cell-cell junctionAmyloid-beta precursor proteinHomo sapiens (human)
synaptic vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
membraneAmyloid-beta precursor proteinHomo sapiens (human)
COPII-coated ER to Golgi transport vesicleAmyloid-beta precursor proteinHomo sapiens (human)
axonAmyloid-beta precursor proteinHomo sapiens (human)
growth coneAmyloid-beta precursor proteinHomo sapiens (human)
platelet alpha granule lumenAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
endosome lumenAmyloid-beta precursor proteinHomo sapiens (human)
trans-Golgi network membraneAmyloid-beta precursor proteinHomo sapiens (human)
ciliary rootletAmyloid-beta precursor proteinHomo sapiens (human)
dendritic spineAmyloid-beta precursor proteinHomo sapiens (human)
dendritic shaftAmyloid-beta precursor proteinHomo sapiens (human)
perikaryonAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
apical part of cellAmyloid-beta precursor proteinHomo sapiens (human)
synapseAmyloid-beta precursor proteinHomo sapiens (human)
perinuclear region of cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
presynaptic active zoneAmyloid-beta precursor proteinHomo sapiens (human)
spindle midzoneAmyloid-beta precursor proteinHomo sapiens (human)
recycling endosomeAmyloid-beta precursor proteinHomo sapiens (human)
extracellular exosomeAmyloid-beta precursor proteinHomo sapiens (human)
receptor complexAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1446628Cytotoxicity against human BT549 cells after 48 hrs by SRB assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Anti-Neurodegenerative Biflavonoid Glycosides from Impatiens balsamina.
AID1446621Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Anti-Neurodegenerative Biflavonoid Glycosides from Impatiens balsamina.
AID1705065Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoi2020European journal of medicinal chemistry, Dec-15, Volume: 208Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors.
AID1446624Cytotoxicity against rat C6 cells assessed as cell viability at 20 uM after 24 hrs by MTT assay relative to control2017Journal of natural products, 02-24, Volume: 80, Issue:2
Anti-Neurodegenerative Biflavonoid Glycosides from Impatiens balsamina.
AID1446627Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Anti-Neurodegenerative Biflavonoid Glycosides from Impatiens balsamina.
AID1484013Inhibition of amyloid beta (1 to 42) (unknown origin) aggregation by Thioflavin-T fluorescence assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.
AID1446623Neuroprotective activity in rat C6 cells assessed as NGF secretion at 20 uM after 24 hrs by ELISA relative to control2017Journal of natural products, 02-24, Volume: 80, Issue:2
Anti-Neurodegenerative Biflavonoid Glycosides from Impatiens balsamina.
AID1446626Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Anti-Neurodegenerative Biflavonoid Glycosides from Impatiens balsamina.
AID1446625Cytotoxicity against human A549 cells after 48 hrs by SRB assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Anti-Neurodegenerative Biflavonoid Glycosides from Impatiens balsamina.
AID1484024Inhibition of amyloid beta (1 to 42) aggregation in Escherichia coli competent cells BL21 (DE3) after overnight incubation by Thioflavin-S steady-state fluorescence assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.
AID1446622Cytotoxicity against mouse BV2 cells assessed as cell viability at 20 uM after 24 hrs by MTT assay relative to control2017Journal of natural products, 02-24, Volume: 80, Issue:2
Anti-Neurodegenerative Biflavonoid Glycosides from Impatiens balsamina.
AID1281980Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by microplate reader analysis2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
α-Glucosidase inhibition and antihyperglycemic activity of flavonoids from Ampelopsis grossedentata and the flavonoid derivatives.
AID1802376Thioflavin-T (Th-T) Fluorescence Assay from Article 10.1074/jbc.M113.464222: \\Site-specific inhibitory mechanism for amyloid u00DF42 aggregation by catechol-type flavonoids targeting the Lys residues.\\2013The Journal of biological chemistry, Aug-09, Volume: 288, Issue:32
Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (372)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (0.81)18.2507
2000's23 (6.18)29.6817
2010's195 (52.42)24.3611
2020's151 (40.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.73 (24.57)
Research Supply Index5.94 (2.92)
Research Growth Index5.91 (4.65)
Search Engine Demand Index103.05 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (35.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.53%)5.53%
Reviews9 (2.39%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other366 (97.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]